# Curacyte

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curacyte

- Industry: Biotechnology
- Headquarters: Munich, Germany
- Website: www.curacyte.eu
- Total disclosed funding: $32M
- Latest round: Series C (Mar 22, 2005)
- Investors on record: 9

## About

Curacyte AG is a specialized company focused on the domain name sales market, providing a platform for secure transactions involving premium domain names, with an emphasis on customer convenience and safety.Curacyte AG operates primarily in the domain name sales sector, facilitating secure transactions for premium domain names. The company is headquartered in Munich, Germany. In May 2008, Curacyte sold its subsidiary, Curacyte Discovery GmbH, to The Medicines Company for EUR 14.5 million. The company's total number of deals stands at 4, with the most recent deal occurring on May 6, 2008. During this time, Curacyte raised a total of EUR 14.5 million through a TRADE SALE, involving The Medicines Company as the investor.Curacyte.eu specializes in the domain name sales market, offering a streamlined platform for the purchase and leasing of domain names. Their core service provides secure transaction facilitation for premium and verified domain names, emphasizing customer convenience and safety throughout the transfer process. The platform caters to a wide array of customers, including individual entrepreneurs, small businesses, and larger enterprises seeking to establish or enhance their online presence, serving clients across various international markets.Curacyte.eu's revenue model centers on direct transactions for domain name sales, ensuring a hassle-free purchasing experience. Clients typically engage through a simple payment structure to acquire domain names at set prices, including notable offerings priced at EUR 100. The company also provides ancillary services such as secure payment processing and transaction support, which enhance customer satisfaction and loyalty. By utilizing a direct-to-consumer sales strategy, Curacyte.eu captures revenue from a diverse range of users, solidifying its position in the competitive domain sales landscape.Looking ahead, Curacyte AG aims to expand its product offerings and enhance its platform functionalities. While specific new products and release dates have not been disclosed, the company is focused on strategic growth in various international markets in the coming years. Recent funding from the TRADE SALE will support these expansion initiatives, particularly in enhancing technology infrastructure to accommodate increased transaction volumes and improve user experience.

## Funding rounds

- Series C, Mar 22, 2005, $17M — AlpInvest Partners, CFH Management, TVM Capital Life Science, BMP, IKB Invest, S-Beteiligungen, Mittelstandische Beteiligungsgesellschaft Sachsen, The Stroh Companies, Inc., GZ Paul Partners B.V.
- Series B, Jun 14, 2002, $6.9M — AlpInvest Partners, TVM Capital Life Science
- Series A, Jun 1, 2000, $8.1M — AlpInvest Partners, TVM Capital Life Science

## Investors

- AlpInvest Partners — Series A, Series B, Series C
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series A, Series B, Series C
- CFH Management (https://capitalatlas.ai/funds/cfh-management) — Series C
- BMP (https://capitalatlas.ai/funds/bmp) — Series C
- IKB Invest (https://capitalatlas.ai/funds/ikb-invest) — Series C
- S-Beteiligungen (https://capitalatlas.ai/funds/s-beteiligungen) — Series C
- Mittelstandische Beteiligungsgesellschaft Sachsen (https://capitalatlas.ai/funds/mittelstandische-beteiligungsgesellschaft-sachsen) — Series C
- The Stroh Companies, Inc. — Series C
- GZ Paul Partners B.V. — Series C